Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

Saved in:
Bibliographic Details
Title: Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.
Authors: Sudha P; Division of Hematolgy and Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN., Pham P; Division of Hematolgy and Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN., Niu W; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN., Liu E; Division of Hematolgy and Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN., Wang L; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN., Truong G; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN., Ligocki C; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN., Al-Azzawi R; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN., Surapenini M; Division of Hematolgy and Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN., Bray SM; Fountain Life Co, Indianapolis, IN., Vetrini F; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN.; Undiagnosed Rare Disease Clinic, Indiana University School of Medicine, Indianapolis, IN., Czader M; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN., Tayeh MK; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN., Lee K; Division of Hematolgy and Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN., Abonour R; Division of Hematolgy and Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN., Suvannasankha A; Division of Hematolgy and Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN., Walker BA; Division of Hematolgy and Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN.; Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN.; Myeloma Division, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL.
Source: Blood advances [Blood Adv] 2026 Jan 13; Vol. 10 (1), pp. 95-105.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025017721